Blockchain-based health data exchange firm Avaneer Health secures $50M in seed funding

Avaneer Health, an interoperable healthcare data exchange company built on blockchain technology, has secured $50 million in seed funding from a number of large healthcare players.

Those backing the Chicago-based network include Aetna, Anthem, the Cleveland Clinic, Health Care Services Corporation, Sentara Healthcare, and the PNC Financial Services Group. The new money will be put into hiring additional team members and technology upgrades required to launch nationwide, the company said Jan. 13.

"Addressing administrative costs and creating a positive consumer experience requires connectivity and the type of data fluidity we have come to expect in other industries," Stuart Hanson, founding CEO of Avaneer Health, said in a statement. "We are very excited to jumpstart our network to enable healthcare organizations to work together with a foundation of trust to solve the 'last mile' problem in healthcare.”

The aforementioned companies, along with IBM, founded the startup in June 2021 and represent 80 million covered patients and 14 million visits per year.

Avaneer's member-based network initiates and streamlines care, helping payers exchange data, assess treatment eligibility, perform prior authorizations and other services.

"To achieve truly frictionless and seamless care, healthcare needs greater transparency and ease of navigation for all parties involved, particularly as we move toward greater adoption of value-based care,” said Tim Skeen, co-chair of Avaneer Health's Board of Directors and senior vice president and CIO of Sentara Healthcare.

""

Matt joined Chicago’s TriMed team in 2018 covering all areas of health imaging after two years reporting on the hospital field. He holds a bachelor’s in English from UIC, and enjoys a good cup of coffee and an interesting documentary.

Around the web

With generative AI coming into its own, AI regulators must avoid relying too much on principles of risk management—and not enough on those of uncertainty management.

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

Trimed Popup
Trimed Popup